|Express information moment information Express information exclusive information Breaking news
TheCurrent affairs information domestic 100 billion CXO (pharmaceutical outsourcing service) leading medicine biology announced a big repurchase!
On the morning of December 6, Yaoming Bio announced that the company was allowed to purchase up to 425 million shares at the Hong Kong Joint Exchange Co., Ltd., accounting for 10%of the total number of shares issued on the day of the shareholders' annual conference.The company's board of directors announced that on December 5, it has decided to use the purchase of repurchase, so as to purchase a shares at a total price of no more than $ 600 million in the open market from time to time.
According to the same flowering data, as of the closing of the noon, Yaoming creatures rose 5.27%to HK $ 31.95/share, with a total market value of 136 billion Hong Kong dollars.
On December 4, Yaoming Bio's "Yaoming Biological Business Update" released on the official website has lowered its performance expectations in 2023.On the evening of the same day, Yaoming Bio issued another announcement saying that the group's business operation and financial conditions maintained a strong momentum, and its business operations and financial conditions had not changed significantly.
Previously lowered performance expectations
Yaoming Bio said that the current transaction price does not reflect its inherent value or the company's actual business prospects, and it is recommended that the purchase of shares also reflects the company's confidence in its own business development prospects.
On the morning of December 4, Yaoming Biological released "Yaoming Biological Business Update" on the official website.The company said that due to biotechnology financing, the industry is expected to increase individual digits in the next two years.Due to the decrease in business revenue of D (drug development) and M (drug production), the company's overall income may not be less than previous expectations.In addition, the slowdown of new capacity climbing and the slowdown in revenue growth will lead to the decline in the company's profits.
On December 4, Yaoming Bio opened sharply and suspended transactions at 10.49. Before the suspension of the transaction, it fell by about 23.79%to HK $ 33.15/share.Industry insiders believe that the above business updates documents or the reasons for the plunge in the stock price of Yaoming biological.
On the evening of December 4, Yaoming Biological announced that the group's business operation and financial conditions maintained a strong momentum, and its business operations and financial conditions had not changed significantly.
"Although the slowdown of biotechnology financing has led to a single -year growth rate of the biotechnology industry, and the growth of target income in 2023 is lower than expected, the company is still optimistic about future prospects. It is expected that the overall income of the group will increase by about 10%in 2023.And will continue to increase capacity and capacity, to maintain strong gross profit and growth rate in 2024 and 2025, "the company said in the announcement.
On December 5, Yaoming Bio resumed trading.The same flowering data showed that Yaoming Biological fell by about 8.45%on the same day, and the turnover rate was about 3.99%.
The prosperity of the CXO industry may be repaired
The new trend of the development of Yaoming biological business this year has attracted much attention.On November 17, Yao Minghelian, which spin -off the self -Minming creature, was listed on the main board of the Hong Kong Stock Exchange. The issue price was HK $ 20.6 per share.After only 4 months of submission of the application for submission, Yao Ming Helian means that the "Yaoming Department" territory expands again.
Chen Zhisheng, CEO of Yaoming Bio and Chairman of Yaominghelian, said that the current income of Yaominghelian accounts for 7%-8%of Yaoming Bio, and spin-off can make Yaoming Helian more flexible and stronger business capabilities.The global biological puppet drug CRDMO (contract research, development and production service) business is developed through an independent financing platform.
According to the information of Fhstrishalvin, according to the income of 2022, Yin Minghe is the world's second largest and the largest CRDMO of biological coupling drugs such as ADC in China, with a market share of 9.8%.Yaoming Helian said that the net income of this listing will be used for the construction of Singapore bases, enhance the production capacity in China, seek strategic alliances, investment and acquisition opportunities, and expand the types and capabilities of Yaoming Helian Technology Platform.
On September 21, Yaoming Bio disclosed the interim report. In the first half of this year, Yaoming's income increased by 17.8%year -on -year to 8.492 billion yuan, and gross profit increased by 4.3%to 3.561 billion yuan year -on -year.The total number of orders (including the unfinished service orders and unfinished potential milestones payment orders) also increased from 18.467 billion U.S. dollars on June 30, 2022 to US $ 20108 million on June 30, 2023.The number of comprehensive projects increased from 534 in the same period last year to 621 on June 30, 2023. The group's business growth was still strong.